Jonathan Fleming

Jonathan Fleming serves as Chairman of the Board for AutonomoUS, Inc., Diceros Therapeutics, Onc.AI, Aquaculture Research Corporation, and EnClear Therapies. Jonathan is also a board member at CONTINUUS Pharmaceuticals, Inc. He is a former President and CEO of Q-State Biosciences and Executive Chairman of QurAlis Inc.

Jonathan was the Managing Partner of Oxford Bioscience Partners for 19 years and has co-founded several neuroscience companies that were later acquired including Synaptic Pharmaceuticals (acquired by Lundbeck); Memory Pharmaceuticals (acquired by Roche); and Hypnion Pharmaceuticals (acquired by Lilly). Prior to joining Oxford Bioscience Partners, he was a Founding General Partner of MVP Ventures in Boston, MA.  He began his investment career with TVM Techno Venture Management in Munich, Germany.  Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early-stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea.

Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers.  Jonathan holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.